Houston- and Seattle-based Indapta Therapeutics has fresh funding to grow its cancer-fighting cell therapy. Photo via Getty Images

A promising cell therapy company has raised its latest funding round — to the tune of $22.5 million.

Indapta Therapeutics, which has a dual headquarters in Houston and Seattle, is a clinical stage biotechnology and next-generation cell therapy company focused on the treatment of cancer and autoimmune diseases. The company announced it has closed a $22.5 million round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer cell therapy.

"This funding will enable us to generate significant additional data in our ongoing trial of IDP-023 in cancer as well as initial data from our first trial in autoimmune disease," Mark Frohlich, Indapta’s CEO, says in a news release.

Indapta has completed enrollment in the safety run-in portion of the Phase 1 clinical trial of IDP-023 in Non-Hodgkin’s Lymphoma and Multiple Myeloma, according to the company. The patients received up to three doses of IDP-023 without and with interleukin (IL)-2.

Completing the round were current investors RA Capital Management, Bayer's impact investment arm Leaps, Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation. Earlier in December, Indapta announced a collaboration with Sanofi to explore the combination of its allogeneic g-NK cell therapy IDP-023 with Sanofi’s CD38 that targets the monoclonal antibody, Sarclisa (isatuximab).

"Preliminary results of IDP-023 in cancer are encouraging and we look forward to initiating our Phase 1 trial for multiple sclerosis in Q1 2025,” Frohlich continues. “This financing, together with our recently announced collaboration with Sanofi, highlights the promise of our differentiated platform.”

Also in August, Indapta announced a FDA clearance of its IND of IDP-023 in combination with ocrelizumab in progressive MS.


Mark Frohlich is the CEO of the Houston- and Seattle-based company. Photo courtesy of Indapta Therapeutics

Houston-based Citroniq Chemicals has secured its series A funding. Photo via Getty Images

Houston company secures $12M series A for decarbonization plant

money moves

A fresh $12 million round of funding will enable Houston-based Citroniq Chemicals to propel planning, design, and construction of its first decarbonization plant.

An unidentified multinational energy technology company led the series A round, with participation from Houston-based Lummus Technology Ventures and cooperation from the State of Nebraska. The Citroniq plant, which will produce green polypropylene, will be located in Nebraska.

“Lummus’ latest investment in Citroniq builds on this progress and strengthens our partnership, working together to lower carbon emissions in the plastics industry,” Leon de Bruyn, president and CEO of Lummus Technology, says in a news release.

Citroniq is putting together a decarbonization platform designed to annually capture 2 million metric tons of greenhouse gas emissions at each plant. The company plans to invest more than $5 billion into its green polypropylene plants. Polypropylene is a thermoplastic resin commonly used for injection molding.

The series A round “is just the first step in our journey towards building multiple biomanufacturing hubs, boosting the Nebraska bioeconomy by converting local ethanol into valuable bioplastics,” says Kelly Knopp, co-founder and CEO of Citroniq.

Citroniq’s platform for the chemical and plastics industries uses technology and U.S.-produced ethanol to enable low-cost carbon capture. Citroniq’s process permanently sequesters carbon into a useful plastic pellet.

Lummus Technology licenses process technologies for clean fuels, renewables, petrochemicals, polymers, gas processing and supply lifecycle services, catalysts, proprietary equipment, and digital transformation.

Geothermal investment is up, but health tech is down — plus more data-backed VC trend from 2024 so far. Photo via Getty Images

Report: Houston's VC trends so far in 2024 and what to watch for the rest of the year

by the numbers

Houston-based geothermal company Fervo Energy accounted for more than half of the venture capital raised by Houston-area startups in the first quarter of 2024.

The region’s VC haul in the first quarter totaled $462.4 million, according to the PitchBook-NCVA Venture Monitor. That’s up from $290.4 million during the same period in 2023 and from $285.8 million in the fourth quarter of last year. Click here to see the Q1 rounds as reported by InnovationMap.

Fervo’s latest funding round, announced in February, represented $244 million (52 percent) of the region’s VC total for the first quarter of 2024.

A report released in March by PitchBook indicated that VC funding last year for geothermal power reached $431 million across 21 deals. As of late February 25 — four days ahead of the Fervo announcement — $165.5 million in VC funding had been pumped into the geothermal sector this year, according to PitchBook.

“The recent VC deal activity with the geothermal power sector underscores a vibrant and evolving market, but still one that garners far less VC than other renewables,” says the report.

In all, Houston-area startups made 38 VC deals in this year’s first quarter, the PitchBook-NVCA Venture Monitor says. That’s down from 42 in the fourth quarter of 2023 and 43 in the first quarter of 2023. Nationwide, the deal count fell sharply in the first quarter of 2024 vs. the first and fourth quarters of last year.

The PitchBook-NVCA Venture Monitor report shows that nationwide, the $36.6 billion in VC investments recorded during the first quarter of 2024 “remained relatively on pace with the past year.”

“However, it would be a mistake to hyperfocus on the results of a single quarter whose results were a bit farther left on the bell curve than usual. The venture capital … business cycle effectively reset in recent years, and as of early 2024, it still appears to be searching for its level,” says the report.

“It is too early to tell where 2024 is going, but the game is on, and America’s VCs are ready for it,” the report adds. “In 2022, our world changed; in 2023, we accepted it was not changing back; and in 2024, we are building what is next.”

In a bit of good news for the Houston area, the report cites cleantech/energy as one of two sectors that venture capitalists should not overlook. The other sector: cybersecurity.

But in a bit of not-so-good news for the region, the report notes a slowdown in VC deals in the healthcare sector over the past two years in the wake of “pandemic-fueled capital exuberance.”

“Yet the healthcare sector differentiates itself from the rest of the market by demonstrating many unmet needs that could have a profound impact on society, particularly around disease diagnosis and treatment,” the report goes on to say. “On top of the immense opportunity set for disruption within healthcare, investor enthusiasm around AI adoption in drug development further speaks to the demand for better solutions in biotech through groundbreaking innovations.”

Following the round, Hello Alice is now valued at $130 million. Photo courtesy Cayce Clifford/Hello Alice

Houston tech platform raises series C round backed by Mastercard

money moves

Hello Alice, a fintech platform that supports 1.5 million small businesses across the country, has announced its series C round.

The amount raised was not disclosed, but Hello Alice reported that the fresh funding has brought the company's valuation to $130 million. Alexandria, Virginia-based QED Investors led the round, and investors included Mastercard, Backstage Capital, Guy Fieri, Golden Seeds, Harbert Growth Partners Fund, How Women Invest I, LP, Lovell Limited Partnership, Tyler “Ninja” and Jessica Blevins, and Tamera Mowry and Adam Housley, per a news release from the company.

“We are thrilled to hit the milestone of 1.5 million small businesses utilizing Hello Alice to elevate the American dream. There are more entrepreneurs launching this year than in the history of our country, and we will continue to ensure they get the capital needed to grow,” Elizabeth Gore and Carolyn Rodz, co-founders of Hello Alice, say in a news release. “In closing our Series C, we welcome Mastercard to our family of investors and continue to be grateful to QED, How Women Invest, and our advocates such as Guy Fieri.”

The funding will go toward expanding capital offerings and AI-driven tools for its small business membership.

“Our team focuses on finding and investing in companies that are obsessed with reducing friction and providing superior financial services solutions to their customers,” QED Investors Co-Founder Frank Rotman says in the release. “Hello Alice has proven time and time again that they are on the leading edge of providing equitable access to capital and banking services to the small business ecosystem."

Hello Alice, which closed its series B in 2021 at $21 million, has collaborated with Mastercard prior to the series C, offering small business owners the Hello Alice Small Business Mastercard in 2022 and a free financial wellness tool, Business Health Score, last year. Mastercard also teamed up with other partners for the the Equitable Access Fund in 2023.

“With Hello Alice, we’re investing to provide support to small business owners as they look to access capital, helping to address one of the most cited business challenges they face,” Ginger Siegel, Mastercard's North America Small Business Lead, adds. “By working together to simplify access to the products and services they need when building and growing their business, we’re helping make a meaningful impact on the individuals who run their businesses, the customers they serve, and our communities and economy at large.”

While Hello Alice's founders' mission is to help small businesses, their own company was threatened by a lawsuit from America First Legal. The organization, founded by former Trump Administration adviser Stephen Miller and features a handful of other former White House officials on its board, is suing Hello Alice and its partner, Progressive Insurance. The lawsuit alleges that their program to award10 $25,000 grants to Black-owned small businesses constitutes racial discrimination. Gore calls the lawsuit frivolous in an interview on the Houston Innovators Podcast. The legal battle is ongoing.

Inspired by the lawsuit, Hello Alice launched the Elevate the American Dream, a grant program that's highlighting small businesses living out their American dreams. The first 14 grants have already been distributed, and Hello Alice plans to award more grants over the next several weeks, putting their grant funding at over $40 million.


NanoTech closed an oversubscribed round of funding, the company announced this week. Photo courtesy of NanoTech

Houston climate-tech startup adds new investors in oversubscribed funding round

cap table additions

A Houston startup that has developed an innovative coating material that can reduce energy consumption has raised fresh funding for its cross-country expansion.

NanoTech Inc. announced its latest funding news — an oversubscribed funding round that brings onboard a handful of new investors. The details of the round were not disclosed, but NanoTech did release that the round included participation from three institutional investors, two corporate-strategic investors, and seven family offices. These entities join initial investor, Austin-based Ecliptic Capital.

NanoTech's flagship product is a waterproof thermal coating, called the Nano Shield Cool Roof Coat, which began rolling out across the country this year. Not only does the product reduce energy costs for the building owner, but it reduces emissions as well.

"It's crucial to recalibrate the sustainability narrative – environmental responsibility and financial return can go hand in hand," says Mike Francis, CEO and co-founder of NanoTech, in a news release. “We’ve transformed the roof from a cost center to a savings source by reducing energy expenditures while also significantly shrinking the building's carbon footprint.”

"The substantial decline in CO2 emissions and energy costs resulting from reduced reliance on HVAC systems is far more than a fringe benefit — it forms the cornerstone of our long-term strategy to lead the climate-resilient materials market. Beyond corporate objectives, it's a personal source of immense pride to foster a healthier planet for generations to come," Francis continues.

As the first selected company in Houston-based Halliburton Labs, NanoTech continues to benefit from the incubator's industrial scaling resources. Francis and Chief Commercial Officer Carrie Horazeck recently joined the Houston Innovators Podcast to discuss the impact their product is making as they roll out nationwide.

"It's just a coating that can go on top of existing structure — any type of commercial roof," Horazeck says on the show. "We have a pretty good amount of data from 2022 showcasing that we can reduce HVAC consumption within the building by about 30 to 40 percent.

"Our clients really see a immediate benefit in their energy bill, and, of course, if you reduce the HVAC consumption, that automatically translates to a decrease in your scope one emissions," she continues.


MacroFab has secured fresh investment to the tune of $42 million. Photo via macrofab.com

Tech-enabled manufacturing startup based in Houston secures $42M in growth financing

show me the money

A Houston company has nearly doubled its total raised with its latest funding round.

MacroFab, a Houston-based electronics manufacturing platform, has announced $42 million in new growth capital led by Foundry and joined by BMW i Ventures, as well as existing investors Edison Partners and ATX Venture Partners. The platform was first launched by Misha Govshteyn and Chris Church in 2015.

“Given MacroFab’s compelling solutions to electronics manufacturing challenges and Foundry’s successful history with parallel companies, our investment is a perfect fit," Foundry Partner Seth Levine says in a news release. "This is a unique opportunity to be part of next generation cloud manufacturing and we’re excited to be joining forces with Misha and his team."

MacroFab built a platform that manage electronics manufacturing and enables real-time supply chain and inventory data. The platform can help customers go from prototype to high-scale production with its network of more than 100 factories across the continent.

“Electronics manufacturing is moving toward resilience and flexibility to reduce supply chain disruptions. These are long term trends recognized by Foundry and BMW i Ventures, who joined this round as investors,” says Govshteyn, MacroFab’s CEO, in a news release. “We are in the earliest stages of repositioning the supply chain to be more localized and focused on what matters to customers most — the ability to deliver products on time, meet changing requirements, and achieve a more sustainable ecological footprint. MacroFab is fundamental to building this new operating model.”

The company has seen significant growth amid the evolution of global supply chain that's taken place over the past few years. According to the company, shipments were up 275 percent year-over-year. To keep up with growth, MacroFab doubled its workforce, per the release, and opened a new facility in Mexico.

“Most companies have felt the pain of inflexible and fragile supply chains," says Daniel Herscovici, partner atEdison Partners, a growth equity firm focused on technology-enabled and SaaS solutions. "MacroFab’s cloud manufacturing platform is transforming contract manufacturing, enabling ‘Made in North America, faster design iteration, and increased supply chain resiliency, among its benefits. Edison Partners shares the company’s vision for addressing this more than $100 billion global market."

Misha Govshteyn, CEO of MacroFab Misha Govshteyn is the founder and CEO of MacroFab. Photo courtesy of MacroFab

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.